In order to confirm the competitive nature of harmol antagonism in a prostate cancer context, we tested the antagonist effects of harmol in PC-3 cells stably overexpressing AR (PALM cells also referred to as PC3 hAR MMTV-luc cells), in the presence of various concentrations of R1881 (0.1, 0.3, 1, 10 nM) using the same transactivation assays (Supplementary Figure S2). This evidence concerns the gene AR and Familial prostate cancer.